Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial.

What Was Tested

The paper reports a study of Cyproterone Acetate and Goserelin, published as a randomized controlled trial.

To investigate the effects of different management strategies for non-localized prostate cancer on men's quality of life and cognitive functioning.

Who Took Part

The study group was 82 patients.

The age groups tagged for this paper are older adults, men only.

Men with prostate cancer were randomly assigned to one of four treatment arms: leuprorelin, goserelin, cyproterone acetate (CPA), or close clinical monitoring.

A community comparison group of men of the same age with no prostate cancer participated for the same length of time.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Cyproterone Acetate study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The men were recruited from public and private urology departments from university teaching hospitals.

All those with prostate cancer who were eligible for hormonal therapy had no symptoms requiring immediate therapy.

In all, 82 patients were randomized and 62 completed the 1-year study, and of the 20 community participants, 15 completed the study.

The main outcome measures were obtained from questionnaires on emotional distress, existential satisfaction, physical function and symptoms, social and role function, subjective cognitive function, and sexual function, combined with standard neuropsychological tests of memory, attention, and executive functions.

What Was Measured

Topics PubMed links to this paper include Androgen Antagonists, Antineoplastic Agents, Hormonal, Cognition Disorders, Cyproterone Acetate, Goserelin, Leuprolide and Prostatic Neoplasms.

What This Means in Plain Language

The paper is a randomized study of Cyproterone Acetate and Goserelin in 82 patients.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2004 (BJU international), a journal based in England.

More context: all human trials.